

## Appendices

Table of Contents	No. of Pages
<a href="#"><u>1 - Preproposal Instructions</u></a>	1
<a href="#"><u>2 - Conference Or Symposium Support Instructions</u></a>	1
<a href="#"><u>3 - Cover Page</u></a>	3
<a href="#"><u>4 - Abstract</u></a>	2
<a href="#"><u>5 - Proposal Table Of Contents</u></a>	1
<a href="#"><u>6 - Detailed Cost Estimate</u></a>	3
<a href="#"><u>7 - Biographical Sketch</u></a>	2
<a href="#"><u>8 - Certificate of Environmental Compliance</u></a>	1
<a href="#"><u>9 - Research Involving Human Subjects and/or Anatomical Substances</u></a>	27
<a href="#"><u>10 - Research Involving Animals</u></a>	5
<a href="#"><u>11 - Safety Program Plan</u></a>	5
<a href="#"><u>12 - Representations for Assistance Agreements</u></a>	4
<a href="#"><u>13 - Certifications and Assurances for Assistance Agreements</u></a>	4

## APPENDIX 1 - PREPROPOSAL INSTRUCTIONS

A. Preproposals should be submitted electronically via an USAMRMC BAA PREPROPOSAL FORM [http://www.usamraa.army.mil/pages/tatrc/new\\_99baapre.cfm](http://www.usamraa.army.mil/pages/tatrc/new_99baapre.cfm)  
You can also submit your preproposal on a PC formatted disk in a format readable by Microsoft Office or Adobe Acrobat.

1. Principal Investigator's Full Name, Address, City, State, Zip, E-mail, FAX and Daytime telephone number.
2. Organization's Full Name, Address, City, State, Zip, E-mail FAX and Daytime telephone number.
3. Preproposal Title (Limited to 120 characters).
4. Six - Eight Keywords
5. Problem to be Studied/Goals and Objectives
6. Significance and/or Uniqueness of the Proposed Effort
7. The Potential Military Relevance
8. Proposed Duration of the Project in Years and Months
9. Names, Title, Roles and Percent of Effort of Participating Personnel.
10. Itemized List of Major Capital Equipment/Subcontracts > \$10K (If Known)
11. Brief Description of Animal and Human Use
12. Conclusions
13. Brief Curriculum Vitae (CV) for PI & Key Personnel

B. If sending on a PC formatted disk, mail to the following address:

US Army Medical Research Acquisition Activity  
ATTN: BAA 02-1  
820 Chandler Street  
Fort Detrick MD 21702-5014

Questions can be answered by calling 301-619-7148 or emailing to:  
[Q&A.BAA@DET.AMEDD.ARMY.MIL](mailto:Q&A.BAA@DET.AMEDD.ARMY.MIL).

## **APPENDIX 2 - CONFERENCE OR SYMPOSIUM SUPPORT INSTRUCTIONS**

A. Conference or Symposium Support requests should be submitted electronically via **USAMRMC BAA 02 CONFERENCE OR SYMPOSIUM SUPPORT FORM** <http://extranet.tatrc.org/usamraa/02conf.html>. The conference or symposium support form information will be received by email. If you do not utilize the html form, you can submit your conference or symposium support request on a PC formatted disk in a format readable by Microsoft Office or Adobe Acrobat.

1. Requestor's Full Name, Address, City, State, Zip, E-mail, FAX and Daytime telephone number.
2. Recipient's Organization's Full Name, Address, City, State, Zip, E-mail, FAX and Daytime telephone number.
3. Conference/Symposium Title (Limited to 120 characters)
4. Start and End Dates of Conference/Symposium
5. City, State and County Where Conference/Symposium will be held.
6. Explanation of Conference and/or benefits/relevance to the mission of USAMRMC
7. Amount of Funds Requested
8. Explanation of funds:
  - (a) Travel expenses of US participants
  - (b) Printing costs (Proceedings, etc.)

**(Note: Funds cannot be provided to reimburse scientists from communist and terrorist countries.)**

9. Include an agenda/tentative program as well as a list of invitees/speakers and their organizations and countries
10. Include Curriculum Vitae (CV) of Chairperson and Co-chairperson, if available

B. If sending on a PC formatted disk, mail to the following address:

US Army Medical Research Acquisition Activity  
ATTN: BAA 02-1  
820 Chandler Street  
Fort Detrick MD 21704-5014

Questions can be answered by calling 301-619-7148 or emailing to:  
[Q&A.BAA@DET.AMEDD.ARMY.MIL](mailto:Q&A.BAA@DET.AMEDD.ARMY.MIL).

## APPENDIX 3 - COVER PAGE

A completed Research Proposal Cover Page must be the first page of the proposal. The Cover Page must contain the information listed below. A suggested format is provided.

1. USAMRMC Log Number. If a preproposal has been submitted, enter the log number that was provided in response to the BAA. If a preproposal was not submitted, leave this blank.
2. Name and Address of Offeror: The full name and address of the organization or institution submitting the proposal should be supplied for this item.
3. Type of Organization: Mark appropriate boxes to indicate type of organization/business.
4. Data Universal Numbering System (DUNS): The code is required and can be obtained by registering with Duns and Bradstreet by calling 800-333-0505 or accessing website [www.dnb.com](http://www.dnb.com).
5. National (NASC): The federal government uses this code to identify specific industries. It can be obtained by calling 800-827-5722 or accessing the website [www.osha.gov/cgi-bin/sic/sicsr5](http://www.osha.gov/cgi-bin/sic/sicsr5).
6. Federal Supply Classifications (FSC): The code tells the government what types of products or services your company provides. The code can be obtained by accessing the website <http://web1.whs.osd.mil/peidhome/guide/mn02/mn02.htm>.
7. Commercial and Government Entity (CAGE): This code is a unique five-character number, which is issued by the Defense Logistics Services Center (DLSC) to identify DOD contractors. You can obtain the number by calling 616-961-4725, Fax 616-961-4388, or by sending an email to [cagemail@dlsc.dla.mil](mailto:cagemail@dlsc.dla.mil).
8. Taxpayer Identification Number (TIN): The TIN is needed for all financial purposes (social security number/employee identification number). (This number can be obtained by calling the IRS at 800-829-1040).
9. Federal Interagency Committee on Education (FICE) Number: This number is required for statistical reporting of federal support to universities, colleges, and selected nonprofit institutions.
10. Proposal Title: Insert title of research proposal not to exceed 120 characters.
11. Estimated Cost: Total cost to complete research effort (including direct and indirect costs).
12. Proposed Start Date: Earliest date principal investigator believes work could begin (at least six months from the submission date).

13. Proposed Duration: Number of years to complete research effort and complete final reports.

14. Proposal Valid Until: Allow a minimum of six months from the date of submission.

15. Principal Investigator's Information: name, address, email, phone and fax.

16. Administrative Representative's Information: name, address, email, phone and fax.

17. Alternate Principal Investigator Information: name and phone

18. Alternate Administrative Representative Information: name and phone

19. Authorized Representative's Information: name, title, signature, and date.

**BAA 02-1 RESEARCH PROPOSAL COVER PAGE**

1. USAMRMC Log No.:		USAMRMC PROPOSAL COVER PAGE	
2. Name and Address of Offeror:		3. Type of Organization: <input type="checkbox"/> EDUCATIONAL: <input type="checkbox"/> HBCU <input type="checkbox"/> MI <input type="checkbox"/> FDP <input type="checkbox"/> COMMERCIAL: <input type="checkbox"/> Large <input type="checkbox"/> Small <input type="checkbox"/> Woman-Owned <input type="checkbox"/> Disadvantaged Business <input type="checkbox"/> NON-PROFIT <input type="checkbox"/> FOREIGN <input type="checkbox"/> OTHER:	
4. Data Universal Numbering System (DUNS):		5. North American Industry Classification System	
6. Federal Supply Classifications (FSC):		7. Commercial and Gov't Entity (CAGE):	
8. Taxpayer Identification No. (TIN):		9. Federal Interagency Committee on Education (FICE) No.:	
10. Proposal Title:			
11. Estimated Cost: \$	12. Proposed Start Date:	13. Proposed Duration	14. Proposal Valid Until:
15. Principal Investigator's Name and Address:		16. Administrative Representative Name & Address:	
Email:		Email:	
Phone No.:		Phone No.:	
FAX No:		FAX No:	
17. Alternate's Name:		18. Alternate's Name:	
Alternate's Phone No:		Alternate's Phone No:	
19. Authorized Representative:			
Typed Name:		Signature:	
Title:		Date Signed:	

**NOTHING ON THIS PAGE IS PROPRIETARY INFORMATION**

## **APPENDIX 4 - ABSTRACT**

A completed Abstract must be the second page of each copy of the proposal.

The Abstract must include the information listed below. A suggested format is also provided.

1. Proposal Title (120 characters maximum)
2. Keywords. 6-8 words.
3. Abstract. Approximately 200 words. If possible nothing on this page should be proprietary or subject to other restrictions on distribution for evaluation purposes.

## BAA 02-1 PROPOSAL ABSTRACT

Proposal Title: *(120 Characters Maximum)*

Keywords: *(6-8 words)*

Abstract: (Type within outline: approximately 200 words)

**NOTHING ON THIS PAGE IS PROPRIETARY INFORMATION**



## **APPENDIX 5 - PROPOSAL TABLE OF CONTENTS**

- A. Research Proposal Cover Page
- B. Abstract
- C. Table of Contents (with pagination)
- D. Statement of Work
- E. Body of Proposal
- F. Detailed Cost Estimate
- G. Addenda
  - 1. Acronym/Symbol Definition
  - 2. Biographical Sketch
  - 3. Personnel Curriculum Vitae
  - 4. Existing/Pending Support
  - 5. Letter Confirming Collaboration
  - 6. Facilities/Equipment Description
  - 7. Human Use
    - a. Optional Form 310, Protection of Human Subjects
    - b. Human Use Documentation (32CFR 219 and 45 CFR 46)
    - c. Copy of all protocols and consent forms
    - d. Documentation of Local Institutional Review Board Review and Approval
  - 8. Animal Use
    - a. Justification for animal/species use
    - b. AAALAC approval or compliance with PHS and Federal
    - c. Current approval letter/minutes from local Institutional Animal Care and Use Committee
    - d. Assurance signed by the Principal Investigator
  - 9. Certificate of Environmental Compliance
  - 10. Other

**NOTHING ON THIS PAGE IS PROPRIETARY INFORMATION**

## APPENDIX 6 – DETAILED COST ESTIMATE

PRINCIPAL INVESTIGATOR (last, first, middle):							
DETAILED BUDGET FOR YEAR *:		<input type="checkbox"/> 1 <sup>ST</sup>	<input type="checkbox"/> 2 <sup>ND</sup>	<input type="checkbox"/> 3 <sup>RD</sup>	<input type="checkbox"/> 4 <sup>TH</sup>	<input type="checkbox"/> 5 <sup>TH</sup>	FROM      THROUGH
PERSONNEL					DOLLAR AMOUNT REQUESTED		
NAME	ROLE ON PROJECT	TYPE APPT. (MONTHS)	ANNUAL BASE SALARY	EFFORT ON PROJECT %	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
	PI						
				%			
				%			
				%			
				%			
				%			
				%			
				%			
				%			
<b>SUBTOTALS</b>							
CONSULTANT COSTS							
MAJOR EQUIPMENT (ITEMIZE)							
MATERIALS, SUPPLIES AND CONSUMABLES (ITEMIZE BY CATEGORY)							
RESEARCH-RELATED PATIENT COSTS							
MEDICAL CARE FOR RESEARCH-RELATED INJURY COSTS							
OTHER DIRECT COSTS (ITEMIZE BY CATEGORY)							
PUBLICATION/REPORTING COSTS							
TRAVEL COSTS							
<b>SUBTOTAL OF DIRECT COSTS FOR THIS BUDGET PERIOD</b>							
CONSORTIUM/ SUBAWARD COSTS		DIRECT COST					
		INDIRECT COST					
<b>TOTAL DIRECT COST FOR THIS BUDGET PERIOD</b>							
TOTAL INDIRECT COSTS FOR THIS BUDGET PERIOD							
<b>TOTAL COSTS FOR THIS BUDGET PERIOD</b>							

\*USE SEPARATE FORM FOR EACH BUDGET YEAR.

Principal Investigator (last, first, middle):

**SUMMARY BUDGET FOR ENTIRE PROPOSED PERIOD OF SUPPORT**

BUDGET CATEGORY TOTALS		INITIAL BUDGET PERIOD	ADDITIONAL YEARS OF SUPPORT REQUESTED				TOTAL
			2 <sup>ND</sup>	3 <sup>RD</sup>	4 <sup>TH</sup>	5 <sup>TH</sup>	
PERSONNEL							
FRINGE BENEFITS							
CONSULTANT COSTS							
MAJOR EQUIPMENT							
MATERIALS, SUPPLIES, AND CONSUMABLES							
RESEARCH-RELATED PATIENT COSTS							
MEDICAL CARE FOR RESEARCH-RELATED INJURY							
OTHER DIRECT COSTS							
TRAVEL COSTS							
SUBTOTAL DIRECT COSTS							
CONSORTIUM/ SUBAWARD COSTS	DIRECT						
	INDIRECT						
TOTAL DIRECT COSTS							
TOTAL INDIRECT COSTS							
TOTAL COST FOR EACH YEAR							*

*\* This amount should agree with the amount entered in block 12 on the Research Proposal Cover Sheet.*

**NOTE:** Itemize all budget categories for each year on the *Justification* page, which follows. Follow Section E, Detailed Cost Estimate under Proposal Preparation in preparing your justification. Use continuation pages as needed.

**NOTE:** Itemize all budget categories for each year on the *Justification* page, which follows. Follow Section E, Detailed Cost Estimate under Proposal Preparation in preparing your justification. Use continuation pages as needed.

## APPENDIX 7 – BIOGRAPHICAL SKETCH

Provide the following information for the key personnel listed on the budget page.			
NAME		POSITION TITLE	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include post-doctoral training).			
INSTITUTION AND LOCATION	DEGREE (IF APPLICABLE)	YEAR(S)	FIELD OF STUDY
<p>RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list in chronological order, previous employment, experience, and honors. Include present membership on any Federal Government public advisory committee. List in chronological order, the titles, all authors, and complete references to all publications during the past 3 years and to representative earlier publication pertinent to this application. If the list of publications in the last 3 years exceeds 2 pages, select the most pertinent publications. PAGE LIMITATIONS APPLY. DO NOT EXCEED 3 PAGES FOR THE ENTIRE BIOGRAPHICAL SKETCH PER INVESTIGATOR.</p>			

RESEARCH AND PROFESSIONAL EXPERIENCE (CONTINUED). PAGE LIMITATIONS APPLY.  
DO NOT EXCEED 3 PAGES FOR THE ENTIRE BIOGRAPHICAL SKETCH PER INVESTIGATOR.

## APPENDIX 8 - CERTIFICATE OF ENVIRONMENTAL COMPLIANCE

The offeror currently ☐ IS ☐ IS NOT (check appropriate category) in compliance with applicable national, state, and local environmental laws and regulations. (If not in compliance, attach details and evidence of approved mitigation measures.)

The offeror has examined the activities encompassed within the proposed action entitled

---

(Enter title and/or Solicitation number and Principal Investigator's name),

for compliance with environmental laws and regulations. The offeror states that the conduct of the proposed action:

A. WILL NOT violate any applicable national, state, or local environmental law or regulation, and

B. WILL NOT have a significant impact on the environment.

The offeror agrees that if the work required under the proposed action at any time results in a significant impact on the environment or a violation of any applicable environmental law or regulation, the offeror will immediately take appropriate action, to include notifying and/or coordinating with the appropriate regulatory agencies as required by law and notifying the Contracting/Grants Officer.

---

Name of Official Responsible for  
Environmental Compliance

---

Signature

---

Title

---

Date

---

Name of Organization

## **APPENDIX 9 - RESEARCH INVOLVING HUMAN SUBJECTS AND/OR ANATOMICAL SUBSTANCES**

This appendix contains the required approvals, forms, and descriptions for research involving human subjects and/or human anatomical substances (including human organs, tissues, cells, body fluids from human subjects as well as graphic, written, or recorded information derived from human subjects). Specific guidelines are subject to change as governing regulations, policies, and procedures are updated. Consult “Guidelines for Research Involving Human Subjects and/or Anatomical Substances” at <http://mrmc-www.army.mil/crprcqhspd.asp> for additional information and updates.

### **Table of Contents**

1. Introduction
2. Definitions
  - 2-a. Research
  - 2-b. Human Subjects
  - 2-c. Human Anatomical Substances
3. Human Subjects Research Review Board
  - 3-a. Review Levels for DOD Sponsored Research
  - 3-b. Timeline and Outcomes
  - 3-c. Multi-site Protocol Review
4. Claim of Exemption
  - 4-a. Approval of Exempt Status for Research Involving Human Subjects or Anatomical Substances
  - 4-b. Exempt Categories
  - 4-c. Claiming Exemption
5. Minimal Risk Research
  - 5-a. Approval of NGTMR Research Involving Human Subjects or Human Anatomical Substances
  - 5-b. Approval of a NGTMR Research Study with a Waiver of Informed Consent
6. Training for Research Investigators
7. Guidelines for Writing Research Protocols Involving Human Subjects
  - 7-a. Title 10 United States Code 980
  - 7-b. Protocol Format



- 7-c. Required Elements of the Protocol
- 7-d. Advertisements, Posters, and Press Releases to Recruit Subjects
- 7-e. Surveys, Questionnaires, and Other Data Collection Instruments
- 8. Informed Consent Document Requirements
  - 8-a. Required Elements of the Informed Consent Document
  - 8-b. Additional Elements of the Informed Consent Document
  - 8-c. Requirements Unique to DOD-Sponsored Research
- 9. Protocol Modifications and Amendments
- 10. Continuing Review and Final Reports
- 11. Serious or Unexpected Adverse Event Reports
- 12. Assurances
- 13. Inclusion of Women and Minorities in Research
- 14. Where to Go for Help and Information
- 15. Claim of Exemption Form
- 16. Protocol Submission Check
- 17. USAMRDC Form 60-R

## **Research Involving Human Subjects and/or Anatomical Substances**

### **1. Introduction**

In 1991, the Department of Defense (DOD), together with 15 other federal agencies, adopted regulations that are known collectively as the Common Federal Rule. These regulations embody the ethical principles of the Belmont Report. Title 32 Code of Federal Regulations Part 219 (32 CFR 219), “Protection of Human Subjects” applies to all research involving human subjects conducted or supported by the DOD. The Department of Health and Human Services (DHHS) National Institutes of Health (NIH) corollary is 45 CFR 46. Research conducted or funded by the U.S. Army Medical Research and Materiel Command (USAMRMC) is also governed by Army Regulation (AR) 70-25, January 1990 and Office of The Surgeon General (OTSG) Regulation 15-2, January 1989. The USAMRMC also adheres to the Food and Drug Administration (FDA) regulation, Title 21 Code of Federal Regulations for research involving investigational drugs or devices. The OTSG maintains the overall responsibility for protecting human research subjects for the Department of the Army.

## **2. Definitions**

### **2-a. Research**

In the Common Federal Rule, research is defined as “. . . a systematic investigation, including research development, testing and evaluation designed to develop or contribute to generalizable knowledge” (32 CFR 219.102). Activities that meet this definition constitute research for purposes of this policy, whether they are conducted or supported under a program that is considered research for other purposes. For example, some demonstration and service programs may include research activities.

The FDA defines clinical investigation as “. . . any experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects” (21 CFR 312.3). This definition applies to research involving the use of FDA-regulated products.

### **2-b. Human Subjects**

In the Common Federal Rule, a human subject is defined as “a living individual about whom an investigator conducting research obtains (1) data through intervention or interaction with the individual or (2) identifiable private information” (32 CFR 219.102).

The FDA defines a human subject as “an individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy individual or a patient” (21 CFR 312.3).

### **2-c. Human Anatomical Substances (and Privileged or Protected Health Information)**

The Common Federal Rule applies to the use of human organs, tissues, cells, or body fluids from individually identifiable human subjects and graphic, written, or recorded information derived from individually identifiable human subjects.

## **3. Human Subjects Research Review Board**

### **3-a. Review Levels for DOD-Sponsored Research**

In addition to first level of review and approval by the local Institutional Review Board (IRB), a second level of review and approval is required for DOD-sponsored research. If a research proposal is recommended for funding and the research involves human subjects, human anatomical substances, or privileged or protected health information, a research protocol must be submitted to the Human Subjects Research Review Board (HSRRB) for review and approval. HSRRB approval must be obtained prior to initiation of the research protocol. The HSRRB is functionally similar to a civilian IRB. The HSRRB is supported administratively by the Office of Regulatory Compliance and Quality, USAMRMC.

If a claim of exemption is submitted, the Acting Chair of the HSRRB will review the protocol and make a determination of exempt status.

If the local IRB has made an assessment that the proposed research is no greater than minimal risk (NGTMR) and the research is eligible for expedited review, the Acting Chair of the HSRRB will review the protocol. If the protocol is not eligible for expedited review, it will receive a full

HSRRB review at a convened Board meeting.

If the local IRB has made an assessment that the proposed research is greater than minimal risk (GTMR), the protocol will receive a full HSRRB review. The protocol must be submitted through the Office of Regulatory Compliance and Quality to the HSRRB for full review and approval prior to initiation of the research.

### **3-b. Timelines and Outcomes**

Initial feedback from the HSRRB is given to the principal investigator within 1 month after submission of a complete protocol packet. After the protocol is approved, any revisions to the protocol, consent form, advertisements, questionnaires, or other related study documentation must be submitted through the local IRB to the HSRRB for approval prior to implementation. The Surgeon General (TSG) of the U.S. Army must approve the recommendations of the HSRRB. The HSRRB will make one of the following recommendations to TSG:

**Approval.** The protocol should be approved without further revisions.

**Conditional Approval.** Approval of the protocol is contingent upon revisions being made and/or additional information being provided. The principal investigator should address the Board's recommendations and submit a revised protocol and related documents to the Acting Chair, who can approve the revised protocol when all of the Board's recommended revisions and requests for additional information have been adequately addressed.

**Disapproval.** A protocol is not approved when there are substantive concerns about the conduct of the protocol and/or safety of the subjects. The principal investigator should address the Board's recommended revisions and requests for additional information and submit a revised protocol and related documents to the Acting Chair for review at another convened meeting of the HSRRB.

**Deferral.** A protocol may be deferred or tabled for action at another meeting when there is a lack of sufficient information to make a more definitive recommendation.

### **3-c. Multi-site Protocol Review**

For multi-site protocols involving the use of human subjects, the protocol and consent form for the primary site are first reviewed and approved by expedited or full Board review as appropriate. If the same protocol used by the primary site will be used at each of the other sites, each site-specific consent form can receive expedited review after review and approval of the protocol and consent form for the primary site. In addition, all domestic and foreign sites are required to assure compliance with the federal policy for the protection of human subjects. If an awardee institution or any of the collaborating sites does not have an assurance number, such as a Multiple Project Assurance (MPA) with the DHHS Office for Human Research Protections, then an application for a DOD single project assurance (SPA) must be completed by each site that does not have an assurance and the application must be submitted to the Human Subjects Protection Branch of the USAMRMC. Refer to part 12, "Assurances" in this appendix for further details regarding submission of an SPA application.

## **4. Claim of Exemption**

### **4-a. Approval of Exempt Status for Research Involving Human Subjects or Anatomical Substances**

Certain categories of research are exempt from review by the HSRRB in accordance with federal guidelines. If your research fits in one or more of these categories, you may request exempt status for your protocol. Your protocol and Claim of Exemption form will be reviewed to evaluate your claim of exemption.

### **4-b. Exempt Categories**

The following list taken from 32 CFR 219.101 details the exemption categories.

1. Research conducted in established or commonly accepted educational settings involving normal educational practices, such as:
  - a. research on regular and special education instructional strategies, or
  - b. research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.
2. Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior, unless:
  - a. information obtained is recorded in such a manner that human subjects can be identified directly or through identifiers linked to the subjects; and
  - b. any disclosure of the human subjects' responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, or reputation.
3. Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior that is not exempt under paragraph 2 of this section, if:
  - a. the human subjects are elected or appointed public officials or candidates for public office, or
  - b. federal statute(s) require(s) without exception that the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter.
4. Research involving the collection or study of existing data, documents, records, pathological specimens or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified directly or through identifiers linked to the subjects.
5. Research and demonstration projects that are conducted by or subject to the approval of Department or Agency heads, and that are designed to study, evaluate, or otherwise examine:
  - a. public benefit or service programs,
  - b. procedures for obtaining benefits or services under those programs,

- c. possible changes in or alternatives to those programs or procedures, or
  - d. possible changes in methods or levels of payment for benefits or services under those programs.
6. Taste and food quality evaluation and consumer acceptance studies,
- a. if wholesome foods without additives are consumed, or
  - b. if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the FDA or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.

#### **4-c. Claiming Exemption**

Investigators who believe that their protocol is exempt from review should submit (1) a completed Claim of Exemption Form and (2) documentation from the local IRB stating that the protocol has been determined to be exempt.

### **5. Minimal Risk Research**

#### **5-a. Approval of NGTMR Research Involving Human Subjects or Human Anatomical Substances**

Minimal risk is defined as “the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical and psychological examinations or tests” in 32 CFR 219.102(i). If the research protocol is assessed as minimal risk in accordance with this definition and regulation, it can be approved by expedited review if the study involves one of the research categories that qualifies for expedited review, as listed in the Federal Register, Notices, Vol. 63, No. 216, dated November 9, 1998. For example, the following is a brief synopsis of these categories:

1. Clinical studies of drugs for which an Investigational New Drug (IND) application is not required or of medical devices for which an Investigational Device Exemption (IDE) application is not required or the medical device has been cleared/approved for marketing and the device is being used for its cleared/approved labeling.
2. Collection of blood samples by finger, heel or ear stick, or by venipuncture, where the amount of blood drawn does not exceed 550 mL in an 8-week period and collection does not occur more frequently than two times per week.
3. Prospective collection of biological specimens for research purposes by noninvasive means, such as hair and nail clippings, teeth extracted as routine patient care, excreta and external secretions, saliva, placenta removed at delivery, amniotic fluid obtained at the time of membrane rupture or during labor, dental plaque and calculus that is not more invasive than routine care, mucosal and skin cells collected by buccal scraping, mouthwashings or swab, and sputum.
4. Collection of data through noninvasive procedures not involving general anesthesia or sedation.

5. Research involving materials, such as data, documents, records or specimens, that have been collected or will be collected solely for nonresearch purposes (e.g. medical treatment or diagnosis).
6. Collection of data from voice, video, digital or image recordings made for research purposes.
7. Research on individual or group characteristics or behavior, or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation or quality assurance methodologies.
8. Continuing review of previously approved research.

#### **5-b. Approval of a NGTMR Research Study with a Waiver of Informed Consent**

A minimal risk protocol approved by expedited review can have the requirement for a written informed consent document waived if it meets the following four criteria, as outlined in 32 CFR 219.116(d):

1. The research involves no more than minimal risk to the subjects.
2. The waiver or alteration will not adversely affect the rights and welfare of the subjects.
3. The research could not practicably be carried out without the waiver or alteration.
4. Whenever appropriate, the subjects will be provided with additional information after participation.

If the local IRB has approved a protocol with waiver of informed consent and the study includes use of human anatomical substances, submit a copy of the consent form used to document individuals' consent to use their tissue, blood, or other medical information or records for research purposes.

#### **6. Training for Research Investigators**

Research investigators must complete appropriate institutional training before conducting human subjects research. Documentation of the most recent ethics training must be submitted for all investigators and other research staff for all protocols. In addition, for all investigational drug and device protocols, documentation of successful completion of a course in the conduct of clinical research in accordance with Good Clinical Practices (GCP) must be submitted for all investigators and other research staff. The most recent ethics training and GCP course must be successfully completed within one year of the planned initiation of the protocol.

#### **7. Guidelines for Writing Research Protocols Involving Human Subjects**

##### **7-a. Title 10 United States Code 980 (10 USC 980)**

Before writing the research protocol, investigators must consider the requirements of 10 USC 980, which are applicable to DOD-sponsored research. 10 USC 980 requires that "Funds appropriated to the Department of Defense may not be used for research involving a human being as an experimental subject unless (1) the informed consent of the subject is obtained in advance, or (2) in the case of research intended to be beneficial to the subject, the informed consent may be obtained from a legal representative of the subject." **Furthermore and consistent**

with the Common Federal Policy for the Protection of Human Subjects, if an individual cannot give his or her own consent to participate in a research study, consent of the individual's legally authorized representative must be obtained prior to the individual's participation in the research. Moreover, an individual not legally competent to consent (e.g., incapacitated individuals, incompetents, minors) may not be enrolled in DOD-sponsored research unless the research is intended to benefit each subject enrolled in the study. For example, a subject may benefit directly from medical treatment or surveillance beyond the standard of care. Proposers should be aware that this law makes placebo controlled clinical trials problematic because of the 'intent to benefit' requirement whenever participation is sought of subjects from whom consent must be obtained by the legally authorized representative.

#### **7-b. Protocol Format**

A detailed research protocol must be submitted for all protocols, including IND or IDE protocols, for human subjects protection review. In addition, the protocol must be reviewed and approved by the local IRB of Record before it can be reviewed by the HSRRB, and the approval letter from the local IRB must be submitted with the protocol for initial HSRRB review.

IND or IDE protocols will follow the format described in the International Conference on Harmonisation (ICH), Consolidated Guideline E6 ([www.ifpma.org/pdf/ifpma/e6.pdf](http://www.ifpma.org/pdf/ifpma/e6.pdf)). Other protocols may follow the ICH Guideline and include applicable paragraphs.

#### **7-c. Required Elements of the Protocol**

1. Protocol Title. The protocol title must be the same as the project/proposal title unless multiple protocols are being submitted within one proposal.
2. Phase. For medical products regulated by the Food, Drug, and Cosmetic Act, designate the protocol as Phase I, II, III, or IV research.
3. Principal Investigator. List the complete name, address, phone number, and email address of the principal investigator. Include a copy of the principal investigator's curriculum vitae (CV) with the protocol. List the names of all personnel who will have significant involvement in the research study; include their practice license (i.e., MD or RN), highest degree(s), job title, and employing institution. In addition, if a Medical Monitor has been assigned to the study, which is required only for greater than minimal risk studies, include his/her name and provide a copy of the current CV.
4. Location of Study. List all centers, clinics, or laboratories where the study is to be conducted. Include the name, degree(s), title, employing institution, and complete address of the investigator(s) for each site.
5. Time Required to Complete. State the month and year of expected start and completion times.
6. Objectives. Provide a detailed description of the purpose and objectives of the study.
7. Study Population.
  - a. Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site (population from which the sample will be recruited/drawn).



b. Describe the methods that will be used to obtain a sample of subjects from the accessible population (i.e., convenience, simple random, stratified random) together with the inclusion and exclusion criteria (include age, gender, ethnicity).

c. If pregnant subjects will be excluded from participation in the study, the method used to determine pregnancy status in women of childbearing potential must be specified. Also, state the time that will elapse between the pregnancy test and exposure to research procedures or medical products and how long the non-pregnant subject should use effective contraceptive practices after participating in the study. Please note that contraceptive practices may be necessary for male subjects participating in certain types of studies. For IND studies, pregnancy testing is required within 48 hours before the start of the study.

8. Protocol Design. Outline the proposed methodology in sufficient detail to show a clear course of action. Technological reliability and validity of procedures should be indicated. Minimum guidance for the plan should include:

a. Subject identification. Describe the code system to be used.

b. Description of the recruitment process. Describe who will identify potential subjects, who will recruit them, and how they will be recruited. Provide copies of all recruitment and advertisement materials for review.

c. Description of the Informed Consent process. Specifically describe the plan for the informed consent process by stating who will perform the informed consent interview, when the interview will take place relative to the participant beginning study participation and in relation to any stressful situation like being informed s/he has cancer, or in relation to the administration of any mind-altering substances such as tranquilizers, conscious sedation, or anesthesia. Address how privacy and time for decision-making will be provided and whether or not the potential subject will be allowed to discuss the study with anyone before making a decision. Indicate who will serve as the witness to the informed consent interview. Please note that a witness is required to be present during the informed consent interview. Two copies of the consent form should be completed so that the subject can get an original copy and a copy can be kept for the PI's study records. A third copy may be needed for the patient's medical record; check with the participating site for specific study-site requirements.

d. Subject assignment (randomization).

e. Evaluations prior to entry. List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation. Please note that some screening procedures may need a separate consent or a two-stage consent process.

f. Evaluations to be made during the conduct of the study (e.g., laboratory evaluations, specimens to be collected, schedule and amounts, storage to include where and whether special conditions are required, labeling, and disposition). For studies using multiple measures or tests over time, it is helpful to display the data collection schedule in a spreadsheet or tabular format.

g. Clinical assessments (e.g., schedule of clinical evaluations and follow-up procedures). Provide a copy of all case report forms, data collection forms, questionnaires, rating scales, and/or interview guides that will be used in the study.



h. Describe the research intervention or activity that the subject will experience. Provide sufficient detail in chronological order for a person uninvolved in the research to understand what the subject will experience.

9. Risks/Benefits Assessment.

a. Describe risks (physical [including pain and discomfort, disfigurement, infection, injury, death], psychological, social, economic, legal, and privacy/confidentiality risks]) associated with the research, measures to be taken to minimize and/or eliminate risks or to manage unpreventable risks and special medical or nursing care that will be needed prior to, during, or following participation.

b. Describe benefits of the research to the subject. If there will be no benefits to the subjects (other than knowing s/he has contributed to science), state this in the protocol and consent form.

c. Payment or compensation for participation is not considered to be a benefit and must be addressed in a separate section.

10. Reporting of serious or unexpected adverse events.

a. Serious or unexpected adverse events can occur in any and all types of studies, not just experimental interventions or clinical trials.

b. Include a definition of what constitutes an adverse event in the study.

(1) For IND or IDE research, include definitions as described in 21 CFR 312.32.

(2) All research protocols must address the following requirements, which is language from HSRRB Clause 7.01:

“An adverse event temporarily related to participation in the study should be documented whether or not considered to be related to the test article. This definition includes intercurrent illnesses and injuries and exacerbations of preexisting conditions. Include the following in all IND safety reports: Subject identification number and initials; associate investigator’s name and name of MTF; subject’s date of birth, gender, and ethnicity; test article and dates of administration; signs/symptoms and severity; date of onset; date of resolution or death; relationship to the study drug; action taken; concomitant medication(s) including dose, route, and duration of treatment, and date of last dose.”

c. Describe agencies or offices to be notified with point of contact information in the event of a serious and unexpected adverse event. For all protocols involving human subjects, including investigational new drug or device studies, the following information about reporting serious and unexpected adverse events, which is language from HSRRB Clause 1.02, must be included in the protocol:

“Adverse experiences that are both serious and unexpected will be immediately reported by telephone to the USAMRMC, Deputy for Regulatory Compliance and Quality (301-619-2165) and send information by facsimile to 301-619-7803). A written report will follow the initial telephone call within 3 working days. Address the written report to the U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RCQ, 504 Scott Street, Fort Detrick, Maryland 21702-5012.”

11. Description of Protocol Drugs or Devices. If the protocol uses an investigational drug or device, provide the following information:

- a. IND/IDE number and name of sponsor.
- b. Complete names and composition of all medication(s), device(s), or placebo(s).
- c. Source of medications, devices, or placebos.
- d. Location of storage for study medications.
- e. Dose range, schedule, and administration of test articles.
- f. Washout period, if used, should be described in detail.
- g. Duration of drug or device treatment.
- h. Concomitant medications allowed.
- i. Antidotes and treatments available.
- j. Disposition of unused drug.
- k. The procedure by which the IND sponsor will monitor the protocol in accordance with 21 CFR 312.

(1) In addition to the above list of requirements to address in the protocol, include the following with the protocol submission: A copy of the Investigator's Brochure and/or device manual and associated case report/data collection forms.

(2) A signed Form FDA 1572 for IND Applications that have been approved by the FDA, including the following information (for non-FDA new drug protocols, the following information should be included in the protocol):

(a) Name, address and a statement of the qualifications for each investigator and the name of each sub-investigator working under the PI.

(b) Names and addresses of facilities to be used.

(c) Name and address of each IRB reviewing the protocol.

(3) For Investigational Devices, include your local IRB's assessment of the risk, such as nonsignificant or significant risk, of the investigational device you plan to use in your study. If the device poses significant risk to research subjects, specify the IDE number obtained from the FDA, the name of the sponsor, and the procedure by which the IND sponsor will monitor the protocol in accordance with 21 CFR 812.

12. Disposition of Data. Describe where data will be stored, who will keep the data, how the data will be stored and the length of time data will be stored. Note that records of IND studies must be kept until 2 years after a New Drug Application is approved/issued, or for 2 years after the IND is withdrawn. Records required for IDE studies should be retained for 2 years after the latter of the following dates: the date that the investigation is terminated or completed and the date that the records are no longer required for support of the pre-market approval application.

For studies with minors, most states require keeping records for up to 7 years (dependent on state's statute of limitations) past the subject's age of majority.

13. Modification of the Protocol. Describe the procedures to be followed if the protocol is to be modified, amended, or terminated before completion. Note that any modification to the protocol, consent form and/or questionnaires must be submitted to both the local IRB and the HSRRB for review and approval. Address this procedure even if you do not anticipate making any modifications.

14. Departure from the Protocol. Describe procedures and notifications to be made in the event of deviations from the approved protocol requirements.

15. Roles and Responsibilities of Study Personnel. Briefly describe the duties of all study personnel, which should include each of the persons listed as investigators, research staff, consultants, and the medical monitor. Describe their roles in the research effort (e.g., Research Coordinator, 80%, recruit and consent subjects, maintain study records, administer study drug, take and record vital signs, enter data into computer data base). Duties of the medical monitor, as defined in HSRRB Clause 8.02, are as follows:

A medical monitor must be assigned to greater than minimal risk protocols. The name and curriculum vitae of the medical monitor, who is someone other than the principal investigator, must be provided. This individual should be a qualified physician who is not associated with the protocol, able to provide medical care to research subjects for conditions that may arise during the conduct of the study, and able to monitor subjects during the conduct of the study. The medical monitor is required to review all serious and unexpected adverse events associated with the protocol and provide an unbiased written report of the event within 10 calendar days of the initial report. At a minimum, the medical monitor should comment on the outcomes of the adverse event and relationship of the event to the test article. The medical monitor should also indicate whether he/she concurs with the details of the report provided by the principal investigator.

The medical monitor will forward reports to the U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RCQ, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

**16. Investigators conducting greater than minimal risk research must include the following description of requirements of the Volunteer Registry Database (HSRRB Clause 2.01) in the protocol and consent form:**

“It is the policy of USAMRMC that data sheets are to be completed on all volunteers participating in research for entry into the U.S. Army Medical Research and Materiel Command Volunteer Registry Database. The information to be entered into this confidential database includes name, address, social security number, study name, and dates. The intent of the database is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRMC; and second, to ensure that the USAMRMC can exercise its obligation to ensure research volunteers are

adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at the USAMRMC for a minimum of 75 years.”

Include in the protocol language to indicate that the Volunteer Registry Data Sheet must be completed. (See Parts 8 and 17 of this appendix.) In addition, include the completion of the data sheets in the study procedure timelines. Once completed, the data sheets must be sent to the following address:

Commanding General, U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-RCQ-HR  
504 Scott Street  
Fort Detrick, Maryland 21702-5012

These data sheets may be submitted annually and upon completion of the study. In addition, some facilities have the capability to enter the information directly and may continue to do so. Use of the Volunteer Registry Data Sheets is not required for exempt or no greater than minimal risk studies, unless otherwise indicated.

#### **7-d. Advertisements, Posters, and Press Releases to Recruit Subjects**

If subjects will be recruited through an advertisement, newspaper article, or similar process, a copy of the local IRB-approved advertisement must be provided.

For studies involving investigational drugs or devices, local IRB review of advertisements is necessary to ensure that the information is not misleading to the subjects participating in IND studies. The FDA has established guidelines on advertisements for subjects. General guidance includes name and address of PI, summary of research purpose, brief eligibility criteria, truthful list of benefits, and the person to contact for further information.

#### **7-e. Surveys, Questionnaires, and Other Data Collection Instruments**

If the research involves surveys, questionnaires, or other instruments, include a copy of the most recent IRB-approved version of each of these documents with the protocol submission. For either of these instruments that is used, the following information at a minimum should be addressed:

The instrument should be labeled with the complete title of the study and instructions for completing and returning the instrument. The instructions should state that the subject can refuse to answer specific items without repercussions. The instrument should be related to the objectives of the study.

Address whether the instrument has been validated.

The instructions and item order should be comprehensible and unambiguous.

Describe the procedure for confidentiality of hardcopy data or electronic data in the protocol and consent form.

## **8. Informed Consent Document Requirements**

### **8-a. Required Elements of the Informed Consent Document**

The format of the informed consent document may vary in accordance with the requirements of the local IRB. However, the informed consent document title must be the same as the protocol title. The following information is required for informed consent documents (32 CFR 219.116 and AR 70-25):

A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures that are experimental.

A description of any reasonably foreseeable risks or discomforts to the subject.

A description of any benefits to the subject or to others, which may reasonably be expected from the research.

A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject.

A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained. For example, describe procedures that will be followed to maintain the subject's privacy and confidentiality, how the identifying information or specimens will be stored and for how long. Also describe who will have access to the identifying data.

Include the following explanation of medical care available for research-related injury:

“Should you be injured as a direct result of participating in this research project, you will be provided medical care, at no cost to you, for that injury. You will not receive any injury compensation, only medical care. You should also understand that this is not a waiver or release of your legal rights. You should discuss this issue thoroughly with the principal investigator before you enroll in this study.”

Three possible mechanisms are available to offset the costs of this requirement:

- a. The proposed recipient may absorb such costs into the institution's operating budget.
- b. The proposed recipient's liability insurance, if available, may be sufficient to cover any medical care costs. The proposed recipient's business office and/or legal advisor must ensure that there is adequate coverage under this liability insurance.
- c. The proposed recipient could negotiate an additional amount of funds, if available, into the award that will cover such medical care cost (such as liability insurance).

If private citizens are enrolled, the following statement should be added to the consent form with the medical care clause:

“Other than medical care that may be provided and any other payment specifically stated in the consent form, there is no other compensation available for your participation in this research.”

The name and contact information for someone to contact (a) about the research, (b) about research subjects' rights, and (c) about a possible research-related injury.

A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.

#### **8-b. Additional Elements of the Informed Consent Document**

When appropriate, one or more of the following elements of information shall also be provided to each subject (32 CFR 219.116 and applicable state/local laws):

A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) that are currently unforeseeable.

Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent.

Any additional costs to the subject that may result from participation in the research.

The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject.

A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.

The approximate number of subjects involved in the study.

Documentation of consent for human immunodeficiency virus (HIV) antibody testing, if scheduled, may be addressed in the body of the consent form or as separate HIV test consent form. Documentation should address any notifications required by state or local laws as well as any specific issues regarding confidentiality of positive test results.

The signature block of the consent form should include a signature line for the subject or legally authorized representative, lines for the permanent address of the subject, and separate lines for the printed name and signature of the witness. On every page of the consent form, except the signature page, include lines for the initials of the subject and the witness.

#### **8-c. Requirements Unique to DOD-Sponsored Research**

##### **Certification of Translation**

Provide documentation that the foreign language version of the consent form is an accurate translation. Documentation of translation must be provided along with the English and foreign language version of the consent forms. The documentation of translation should include the following statement, "I certify that this is an accurate and true translation" as well as the signature, name, address, phone number and, if available, fax number of the translator.

## **Sample Donation**

If the samples donated in this study will be used in other studies, the following statement should be included in the consent form:

“During this study, you will be asked to provide \_\_\_\_\_ (clearly specify the type of samples to be provided). These samples will be used for \_\_\_\_\_ (enter all known and anticipated uses) and may also be used for purposes that are currently unknown. There is a chance that the samples that you are donating under this study may be used in other research studies and may have some commercial value. (If a commercial value is anticipated, that value should be clearly described at this point.) Should your donated sample(s) lead to the development of a commercial product, \_\_\_\_\_ will own it and may take action to patent and license the product. \_\_\_\_\_ does not intend to provide you with any compensation for your participation in this study nor for any future value that the sample you have given may be found to have. You will not receive any notice of future uses of your sample(s). (When the study involves treatment as well as research, the following language should be added: You may agree to participate in the research protocol, but refuse to provide the additional samples discussed above.).”

In addition, a donation form may be prepared for signature by the volunteer and a witness that states:

“As a participant in \_\_\_\_\_ (insert the title of the study), I voluntarily donate any and all \_\_\_\_\_ (clearly specify the type of sample(s) to be provided) to \_\_\_\_\_. These samples will be used for (enter all known and anticipated uses) and may also be used by \_\_\_\_\_ for uses not currently known to me. There is a possibility that the samples that I am donating under this study may be used in other research studies and may have some commercial value. (If a commercial value is anticipated, that value should be clearly described at this point). Should my donated sample(s) lead to the development of a commercial product, \_\_\_\_\_ will own it and it is possible that it will be patented and licensed by \_\_\_\_\_. \_\_\_\_\_ does not intend to provide me any compensation for this and will not give me any notice of future uses of my sample(s).”

Please note that a separate sample donation form is not required. If you choose not to draft a separate sample donation form, the language from the first paragraph of this clause must be included in the informed consent document.

## **Payment for Study Participation: Active Duty Military Personnel**

Under 24 USC 30, payment to Active Duty military personnel for participation in research is limited to blood donation and may not exceed \$50 per blood draw. Active duty research subjects may not receive any other payment for participation in a research study.

## **Confidentiality**

The following statement must be included in the consent form for all protocols that enroll military personnel:

“All data and medical information obtained about you, as an individual, will be considered privileged and held in confidence; you will not be identified in any presentation of the results. Complete confidentiality cannot be promised to subjects, particularly to subjects who are

military personnel, because information bearing on your health may be required to be reported to appropriate medical or command authorities.”

For studies involving civilian subjects and their donated samples, include language describing how the subject’s confidentiality will be maintained, how long the samples will be retained, and who will have access to the samples. In addition, include language from HSRRB Clause 11.01-Review of Research Records, which states:

“It should be noted that representatives of the U.S. Army Medical Research and Materiel Command are eligible to review research records as a part of their responsibility to protect human subjects in research.”

### **Pregnant Women**

If pregnant women will be excluded, the following statement must be included if pregnancy during or after the study constitutes a risk to the participant or fetus:

“I should avoid becoming pregnant for at least (time period in days, weeks, or months) after participation in the study. To avoid becoming pregnant, I should either abstain from sexual relations or practice a method of birth control. Except for surgical removal of the uterus, birth control methods such as the use of condoms, a diaphragm or cervical cap, birth control pills, IUD, or sperm-killing products are not totally effective in preventing pregnancy.”

### **Volunteer Registry Database**

For all studies involving greater than minimal risk, notification regarding the requirements of the Volunteer Registry Database, must be included in the consent form. The Volunteer Registry Database contains items of personal information, such as names, addresses, social security number, and the name of the respective study. Information in the database will only be disclosed in accordance with Army Regulation 340-21 (the Army Privacy Program) and the Privacy Act of 1974. This means that only a person for whom data is collected, or his/her designated agent or legal guardian may request information from the database. Only authorized staff of the Office of Regulatory Compliance and Quality have access to information stored in the database.

The USAMRDC Form 60-R must be completed for each volunteer. Send all completed forms to the Human Subjects Protection Branch annually and at the completion of the study. An example of the form is located in part 17 of this appendix. The following statement is normally included in the “Confidentiality” section of the consent form:

“It is the policy of USAMRMC that data sheets are to be completed on all volunteers participating in research for entry into this Command’s Volunteer Registry Database. The information to be entered into this confidential database includes name, address, social security number, study name, and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual’s participation in research sponsored by USAMRMC; and second, to ensure that the USAMRMC can exercise its obligation to ensure research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRMC for a minimum of 75 years.”



## **9. Protocol Modifications and Amendments**

As a second level review Board, the HSRRB continues to monitor protocols after the initial approval notification. All modifications to the protocol, consent form and/or questionnaires must be submitted to the HSRRB for review and approval prior to implementation. A list of proposed modifications or amendments to the protocol and an explanation of the need for these modifications should be submitted. The level of review required for approval depends on the nature of the modifications.

## **10. Continuing Review and Final Reports**

All continuing review reports and the final report approved by the local IRB must be submitted to the HSRRB. A continuing review of the protocol must be completed by the local IRB at least once each year for the duration of the study.

## **11. Serious or Unexpected Adverse Event Reports**

Include in the initial adverse event reports the name of the person submitting the report, if different from the PI, name of the study, the HSRRB log number (A-xxxx) assigned to the study, the number of subjects enrolled to date, and the number and type of serious and unexpected adverse events previously reported in the study.

If the adverse event occurs in an IND study, the initial report must be identified as the “Initial Report for Subject (# or initials) enrolled in the clinical study Title and Log

No. A-XXXX under IND #.”

The following information must be provided:

(1) Description of Study. Double or single blind. If the study is being conducted in phases, indicate what phase of the study the subject is participating in.

(2) Number of subjects enrolled. Total enrollment at the time of the adverse event.

(3) Synopsis of event. Provide a complete narrative of the event.

(4) Subject status. Did the subject recover? What was the patient status at the time of the report?

(5) Other serious and unexpected adverse events from this study. Please provide any information pertaining to other adverse events that may have occurred during the conduct of this study.

(6) Most frequently expected adverse events based on the nature of the product. What adverse events would you expect to see based on the nature of the product or based on information contained in the most current version of the Investigator’s Brochure.

(7) Actions taken in response to the adverse event. Is the subject still enrolled in the study or have they been dropped? Were any modifications or changes made to the protocol in response to the event? Provide an assessment of the relationship of the adverse event to the subject’s participation in the study.

(8) Identification of the individual who completed the report. Include the signature, printed name and identity (investigator, study physician, etc.) of the individual who is providing the information.

In addition to the initial report of the adverse event, the report of the medical monitor must include his/her evaluation of the relationship of the adverse event to the subject's participation in the study and a follow-up report describing the resolution of the adverse event.

## **12. Assurances**

If an institution has a current MPA or Cooperative Projects Assurance (CPA) with the DHHS Office for Human Research Protections, submit a letter with the following protocol information: (a) MPA number, (b) risk level that the IRB classified the protocol (no greater than minimal risk or greater than minimal risk), (c) date of IRB approval, and (d) next continuing review date. This letter must be on official, institutional letterhead stationary and signed by the chairperson of the IRB that approved the protocol.

If the institution does not have a current MPA or CPA with the Office for Human Research Protections, a written Assurance of Compliance must be filed with the Human Subjects Protection Branch of the Office of the Deputy Chief of Staff for Regulatory Compliance and Quality. The obligation to obtain an assurance can be found in 32 CFR 219.103.

There are four requirements for a DOD SPA that must be submitted to the Human Subjects Protection Branch. The first is to complete a DOD SPA application. This application can be found at <http://mrmc-www.army.mil/cprcqhspd.asp>.

The second requirement is to provide a table of the IRB membership with the credentials (e.g. M.D., Ph.D., etc.) of each member with his or her affiliation with the institute and the role fulfilled on the IRB (e.g. chairperson, alternate, scientist, etc.). An example of this table is provided in the SPA application.

The third requirement is to provide short CVs or biographical sketches of all of the IRB members. These CVs are used to verify qualifications of the IRB members. The last requirement is to provide the written policies and procedures for conducting its initial and continuing review of research that are used by the IRB as outlined in 32 CFR 219.103. The SPA number will be issued after the protocol is approved by the HSRRB.

A letter from the Chairperson of the IRB that approved the protocol must accompany the SPA application on official, institutional letterhead stationary. The risk level assigned to the protocol by the IRB must be included along with the date of approval by the IRB and the next continuing review date.

## **13. Inclusion of Women and Minorities in Research**

Consistent with the Belmont Report and recent congressional legislation, special attention is given to inclusion of women and minorities in research funded or managed by the USAMRMC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. If women and/or minorities will be excluded from the protocol, a justification must be included.

## 14. Where to Go for Help and Information

If your research involves human subjects, you should first contact your local IRB for institutional requirements. If you have questions regarding the HSRRB protocol and consent form requirements or the review and approval process, contact the Office of Regulatory Compliance and Quality at the address or phone number listed below.

Phone: 301-619-2165/2166

Mail: Commanding General, U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-RCQ-HR  
504 Scott Street  
Fort Detrick MD 21702-5012

### References:

- Title 32 Code of Federal Regulation, Part 219, Protection of Human Subjects
- Title 21 Code of Federal Regulation, Part 50, Protection of Human Subjects
- Title 21 Code of Federal Regulation, Part 56, Institutional Review Boards
- Title 21 Code of Federal Regulation, Part 312, Investigational New Drug Application
- Title 21 Code of Federal Regulation, Part 812, Investigational Devices
- Title 45 Code of Federal Regulation, Part 46, Subparts B, C, and D, Protection of Human Subjects
- Code of Federal Regulations is located at [www.access.gpo.gov/nara/cfr/index.html](http://www.access.gpo.gov/nara/cfr/index.html)
- Army Regulation 70-25, Use of Volunteers as Research Subjects
- Army Regulation 40-7, Use of Investigational Drugs and Devices in Humans and the Use of Schedule I Controlled Drug Substances
- Army Regulations can be located at [www.usapa.army.mil](http://www.usapa.army.mil)
- Office of The Surgeon General Regulation 15-2, Human Subjects Research Review Board
- Title 10 United States Code, Section 980
- Department of Defense Directive 3216.2
- International Conference on Harmonisation, Good Clinical Practice, Consolidated Guideline is located at [www.ifpma.org/pdfifpma/e6.pdf](http://www.ifpma.org/pdfifpma/e6.pdf); all other ICH guidelines can be found in the ICH home page located at [www.ifpma.org/ich1.html](http://www.ifpma.org/ich1.html)

Copies of the preceding references can be obtained from either the U.S. Government Printing Office or the National Technical Information Service at:

Phone: 202-512-1800  
Web Site: [www.access.gpo.gov/su\\_docs](http://www.access.gpo.gov/su_docs)  
Mail: Superintendent of Documents  
P.O. Box 371954

Pittsburgh, PA 15250-7954  
Phone: 703-605-6000; 800-553-NTIS  
E-mail: [orders@ntis.fedworld.gov](mailto:orders@ntis.fedworld.gov)  
Mail: National Technical Information Service  
5285 Port Royal Road  
Springfield, VA 22161

## 15. Claim of Exemption Form

PROTOCOL TITLE:	
PRINCIPAL INVESTIGATOR'S NAME:	PROPOSAL NO:
INSTITUTION:	

1. Will existing or archived data, documents, medical records, or database records be used? Yes No

2. Will biological specimens (e.g., cells, tissues, blood) be used? Yes No

3. Indicate below the sources of existing or archived data or biological specimens or cell lines (e.g., cell lines purchased from ATCC).

---

---

4. Will the donors of the original biological specimens be able to be identified, directly or indirectly, through identifiers linked to the donor? Yes No

5. Will data be recorded in writing? Yes No

6. Will data be recorded by audiotape? Yes No

7. Will data be recorded by videotape? Yes No

8. If survey instruments are used, will sensitive or private topics be explored? Yes No

9. Will subjects be identifiable either by name or through demographic data? Yes No

If the answer to any question 4-9 is yes, describe on a separate sheet of paper how the confidentiality of a subject's identity will be maintained. Also describe plans for maintaining or destroying identifying links to subjects after the protocol has been completed.

---

Principal Investigator's Signature

Date

## 16. Protocol Submission Checklist

PROTOCOL TITLE:	
PRINCIPAL INVESTIGATOR'S NAME:	PROPOSAL NO:
INSTITUTION:	

### Requirement for All Protocols as Appropriate:

- ☐ Research Protocol
- ☐ Consent Form(s)
- ☐ Curriculum Vitae or Biosketch for Principal Investigator and Medical Monitor
- ☐ Documentation of the most current ethics training for all research staff
- ☐ Scientific Review/Peer Review Approval(s)
- ☐ Letter from the IRB Chairperson with the following protocol information: (a) MPA number, (b) risk level that the IRB classified the protocol (exempt, NGTMR, GTMR), (c) date of IRB approval, (d) next continuing review date, and (e) risk for medical devices (nonsignificant risk or significant risk).
- ☐ Recruitment advertisements, posters, and announcements
- ☐ Case report form(s), data collection/recording form(s), questionnaires, interview guides, etc.
- ☐ Radiation Control Committee/Biosafety Review Report
- ☐ Data Collection Forms and Case Report Forms
- ☐ **If potential commercial use of sample(s) or future use of sample(s) in other studies**, a Sample Donation is required to be in the consent form.
- ☐ With HIV Testing, documentation of consent for HIV antibody testing, if scheduled, may be addressed in the body of the consent form or as separate HIV test consent form.

### Additional Requirements for IND Protocols:

- ☐ Documentation of the Investigator's most recent GCP training
- ☐ Document specifying IND Number
- ☐ Investigator's Brochure
- ☐ Copy of Case Report Forms (blank)

## Protocol Submission Checklist (cont.)

### Additional Requirements for Medical Device Protocols:

- \_\_\_ Documentation of the Investigator's most recent GCP training
- \_\_\_ Document from manufacturer declaring level of risk for device (non-significant risk or significant risk) and IDE form
- \_\_\_ Document specifying IDE Number
- \_\_\_ Manufacturer's device manual/ device information

### What type of study is proposed?

- |                              |                                  |                            |
|------------------------------|----------------------------------|----------------------------|
| ___ Phase I Clinical Trial   | ___ Survey/Medical Record Review | ___ Community Intervention |
| ___ Phase II Clinical Trial  | ___ Cohort (longitudinal study)  | ___ Laboratory Experiment  |
| ___ Phase III Clinical Trial | ___ Retrospective (case-control) | ___ Tissue Only            |
| ___ Multicenter Trial        | ___ Program/Policy Study         | ___ Qualitative Study      |
| ___ Pilot Study              | ___ Cross-Sectional (prevalence) | ___ Other: _____           |

### Check all procedures applicable to this protocol:

- |   |                                       |
|---|---------------------------------------|
| ___ Experimental Drug/Medications IND# _____      | ___ Prosthetic Orthopedic Devices     |
| ___ Marketed Agent, but Unapproved Use IND# _____ | ___ Nutrition/Metabolism Study        |
| ___ Experimental Device, IDE# _____               | ___ Tissue/Organ Transplant           |
| ___ Immunological Study                           | ___ Radiation or Radioactive Material |
| ___ Artificial Organ Study                        | ___ Human Embryos                     |
| ___ Experimental Treatments                       | ___ Diagnostic Procedures             |
| ___ Experimental Surgery                          | ___ Anatomical Substances             |
| ___ Biological Specimens                          | Other: _____                          |
| Drug (s) to be used: _____                        | Drug Type* _____                      |
| _____   | _____                                 |
| _____   | _____                                 |

\*Drug Type may be chosen from the following list or other type may be stated as appropriate:

Analgesics	Anti-cancer drugs	Cardiac drugs	Hematologic agents
Anesthetics	Anti-convulsants	Diuretics	Hormones
Anti-allergy drugs	Anti-hypertensive drugs	Drugs affecting respiration	Tranquilizers/psychotropic drugs
Anti-arrhythmic drugs	Anti-Parkinson agents	Eye/Optical drugs	Vitamins/Minerals
Antibiotics/anti-infective agent	Autonomic drugs	Gastrointestinal drugs	

## Protocol Submission Checklist (cont.)

### Human Subject Information:

Age range of subjects: \_\_\_\_\_

Total number of subjects expected to be enrolled: \_\_\_\_\_

Total number of subjects at each collaborating site: \_\_\_\_\_

Check all that apply:

Subject Gender:

☐ Male

☐ Female

Are subjects able to provide their own consent?

☐ Yes

☐ No

Vulnerable Subject Class:

☐ Prisoners

☐ Minorities

☐ HIV positive

☐ Psychologically impaired

☐ Impaired decision-making

☐ Psychiatric patient

☐ Military

☐ Employee/Student

☐ Trauma

Subject Recruitment:

☐ In-patients

☐ Out-patients

☐ Students/employees

☐ Paid volunteers

Other:

---

Principal Investigator's Signature



## 17. USAMRDC Form 60-R

**VOLUNTEER REGISTRY DATA SHEET (USAMRDC 60-R)**

**THIS FORM IS AFFECTED BY THE PRIVACY ACT OF 1974**

1. **AUTHORITY:** 5 USC 301; 10 USC 1071-1090; 44 USC 3101; EO 9397
2. **Principal and Routine Purposes:** To document participation in research conducted or sponsored by the U.S. Army Medical Research and Materiel Command. Personal information will be used for identification and location of participants.
3. **Mandatory or Voluntary Disclosure:** The furnishing of the SSN is mandatory and necessary to provide identification and to contact you if future information indicates that your health may be adversely affected. Failure to provide information may preclude your participation in the research study.

**PART A - INVESTIGATOR INFORMATION**

**(To Be Completed By Investigator)**

**PLEASE PRINT, USING INK OR BALLPOINT PEN**

1. Study Number: \_\_\_\_\_ 2. Protocol Title: \_\_\_\_\_
3. Contractor (Laboratory / Institute Conducting Study): \_\_\_\_\_
4. Study Period: From: \_\_\_\_/\_\_\_\_/\_\_\_\_ To: \_\_\_\_/\_\_\_\_/\_\_\_\_  
DD MM YY DD MM YY
5. Principal / Other Investigator(s) Names(s): \_\_\_\_\_
6. Location / Laboratory \_\_\_\_\_
1. \_\_\_\_\_
2. \_\_\_\_\_
3. \_\_\_\_\_

## PART B - VOLUNTEER INFORMATION

**(To Be Completed by Volunteer)**

**PLEASE PRINT, USING INK OR BALLPOINT PEN**

7. SSN: \_\_\_\_/\_\_\_\_/\_\_\_\_ 8. Name: \_\_\_\_\_
9. Sex: M\_\_\_\_F\_\_\_\_ 10. Date of Birth: \_\_\_\_/\_\_\_\_/\_\_\_\_ 11: \*MOS/Job Series\_\_\_\_ 12: Rank/Grade \_\_\_\_\_
13. Permanent Home Address (Home of Record) or Study Location:

<hr/>		<hr/>	
(Street)		(P.O. Box / Apartment Number)	
<hr/>		<hr/>	<hr/>
(City)	(Country)	(State)	(Zip Code)

Permanent Home Phone Number:

- 14. \* Local Address (If Different From Permanent Address):**

<b>(Street)</b>		<b>(P.O. Box / Apartment Number)</b>	
<b>(City)</b>	<b>(Country)</b>	<b>(State)</b>	<b>(Zip Code)</b>

**Local Phone Number:** \_\_\_\_\_

15. \* Military Unit: \_\_\_\_\_ Zip Code: \_\_\_\_\_
- Organization: \_\_\_\_\_ Post: \_\_\_\_\_ Duty Phone Number: \_\_\_\_\_

## VOLUNTEER REGISTRY DATA SHEET (USAMRDC 60-R) (continued)

### PART C - ADDITIONAL INFORMATION (To Be Completed by Investigator)

PLEASE PRINT, USING INK OR BALLPOINT PEN

16. Location of Study: \_\_\_\_\_

17. Is Study Completed: Y: \_\_\_\_\_ N: \_\_\_\_\_

Did volunteer finish participation: Y: \_\_\_\_\_ N: \_\_\_\_\_ If YES, date finished \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
DD MM YY

If NO, date withdrawn: \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Reason Withdrawn:  
DD MM YY

18. Did any Serious or Unexpected Adverse Incident or Reaction Occur: Y: \_\_\_\_\_ N: \_\_\_\_\_ If YES, Explain:

19. \* Volunteer Follow-up: \_\_\_\_\_

Purpose: \_\_\_\_\_

Date: \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Was contact made: Y: \_\_\_\_\_ N: \_\_\_\_\_ If no action taken, explain:

20. \* Hard Copy Records Retired: Place: \_\_\_\_\_ File NR: \_\_\_\_\_

21. \* Product Information:

Product: \_\_\_\_\_

Manufacturer: \_\_\_\_\_

Lot #: \_\_\_\_\_ Expiration Date: \_\_\_\_\_

NDA #: \_\_\_\_\_ IND/IDE #: \_\_\_\_\_

\*Indicates that item may be left blank if information is unavailable or does not apply. Entries must be made for all other items.

When completed, a copy of this form should be sent to the address below:

Commander  
U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-RCQ-HR  
Fort Detrick, MD 21702-5012

## APPENDIX 10 - RESEARCH INVOLVING ANIMALS

### Table of Contents

1. Introduction
2. Alternatives to Painful Procedures
3. Literature Search for Duplication
4. Rationale for Using Animals
5. Species Identification and Rationale
6. Number of Animals Used
7. Rationale for the Number of Animals Required
8. Experimental Design
9. Technical Methods (Animal Procedures)
10. Anesthesia/Analgesia/Tranquilization
11. Study Endpoint
12. Euthanasia or Final Disposition
13. Institutional Animal Care and Use Committee(s) (IACUC) Approval
14. U.S. Department of Agriculture (USDA) Inspection Report
15. Qualifications
16. Accreditation
17. Principal Investigator Assurances

### Research Involving Animals

#### 1. Introduction

**If using animals, provide all information required by this appendix. Any and all subcontractors using animals must also provide the information required by this appendix.**

DOD definition of animal: **Any live nonhuman vertebrate.**

The DOD Directive 3216.1, dated April 17, 1995, provides policy and requirements for the use of animals in DOD-funded research. **These requirements may differ from those of other funding agencies.** Each of the following items **must** be addressed in a proposal appendix entitled "Research Involving Animals." Questions concerning animal use should be directed to Ms. Joyce O'Brien:

Phone: 301-619-2144

Fax: 301-619-4165

Email: [joyce.obrien@det.amedd.army.mil](mailto:joyce.obrien@det.amedd.army.mil)

Mail: U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-RCQ-AR  
504 Scott Street  
Fort Detrick, MD 21702-5012

## **2. Alternatives to Painful Procedures:**

A painful procedure is defined as any procedure that would reasonably be expected to cause more than slight or momentary pain and/or distress in a human being to which that procedure is applied. The Animal Welfare Act regulations specifically state that the Principal Investigator (P.I.) must provide a narrative description of the methods and sources, e.g., the Altweb (Johns Hopkins Center for Alternatives to Animal Testing), MEDLINE, Life Sciences Abstracts, AGRICOLA, and BIOSIS) that he/she used to determine that alternatives to the painful/distressful procedure, including those procedures in which pain/distress is alleviated, were not available. The minimal written narrative must include: databases searched or other sources consulted, date of the search and the years covered by the search, key words and/or search strategy used and a discussion of what alternatives were considered but not used. Where Federal law requires specific testing procedures, state the appropriate CFR or legal guidance that requires this testing. (The USAMRMC reserves the right to request evidence that a literature search for alternatives to painful procedures was performed.)

## **3. Literature Search for Unnecessary Duplication:**

This search must be performed to prevent unnecessary duplication of previous experiments. A search of the following databases is required: Biomedical Research Database (BRD) at [www.dtic.mil/biosys/org/brd](http://www.dtic.mil/biosys/org/brd) and the Computer Retrieval of Information of Scientific Projects (CRISP) at [www.crisp.cit.nih.gov](http://www.crisp.cit.nih.gov) or the Federal Research in Progress (FEDRIP) at <http://grc.ntis.gov>. Additional searches in databases specific to the area of research performed in your proposal are highly recommended. Information on your search for duplication must include databases searched, keywords or search strategy used, period of search, and date search was performed.

## **4. Rationale for Using Animals:**

Provide a scientific justification for using animals in the proposed research. State alternatives to animal use that you considered, such as computer modeling or cell cultures, and explain why these alternatives cannot be used to obtain the research objectives. **It is USAMRMC policy that alternatives to the use of animals be thoroughly investigated prior to submission of any proposal involving animals.**

## **5. Species Identification and Rationale:**

Identify the species of animals used. If using mice, rats or guinea pigs, state the strain. If using dogs, cats or rabbits, state the breed. Provide a scientific justification for their use. Explain why you selected this particular animal model. What unique morphological and physiological characteristics does this animal model possess that make it the best choice?

## 6. Number of Animals Used:

State number of groups, number of animals in each group and the total number of animals used by species. Additionally, provide the following information:

- a. State the common names and number of animals used in research involving no pain, distress or use of pain-relieving drugs.
- b. State the common names and numbers of animals used in research involving pain or distress that is relieved with anesthetics and/or analgesics.
- c. State the common names and numbers of animals used in research involving pain or distress that is NOT relieved with anesthetics and/or analgesics.

## 7. Rationale for the Number of Animals Required:

Describe the statistical methodology used to determine group size and total number of animals used. Include animals necessary for controls, technique development, expected losses, etc. Explain how **these numbers were statistically determined to be the minimum** required to obtain valid scientific results. State the statistical test(s) planned or describe the strategy intended to evaluate the data. Where Federal law or regulations require specific group sizes, state the appropriate CFR or reference.

## 8. Experimental Design:

Provide a complete description of experimental design to include a summary table of experimental groups and a flowchart indicating sequence of experimental events. Succinctly outline the formal scientific plan and direction of experimentation. If several experiments or sequential studies are included in the protocol, describe the experimental design of each separately. The number of animals listed in this section must correspond to the total number of animals requested in paragraph 6

## 9. Technical Methods (Animal Procedures):

Provide a complete description of all procedures the animals will experience. Include surgical procedures, biosamples (i.e., frequency, volume, harvest site, and collection method), adjuvants, tissue sampling for DNA analysis (i.e., age of sampling, amount of tissue taken, anesthetic use) and injections (i.e., agent, dosage, route, and anatomical site of administration). State frequency of animal observation once experimental procedures start and describe health status assessment criteria used. When using Complete Freund's Adjuvant and/or *in vivo* production of monoclonal antibodies, provide a scientific justification and state what alternatives you considered and why they were not used. If prolonged restraint, food or water restriction, or multiple major survival surgeries are performed during the protocol, provide a scientific justification.

## 10. Anesthesia/Analgesia/Tranquilization

Describe the methods or strategies planned to effectively relieve pain and distress. If analgesics are used for pain/distress relief provide the time schedule for administration and the observation criteria utilized to determine if the animals are experiencing pain and/or distress. State the drug's name, dosage, frequency, route, and anatomical site of administration. Additional scientific justification is required if the following agents are used: neonatal hypothermia, chloral hydrate,

alpha-chloralose, ether or urethane. If anesthetic/analgesic agents are not used, provide an explanation.

#### **11. Study Endpoint:**

State the projected study endpoint for the animals (e.g., recovery, euthanasia, use in another protocol). Define specific health assessment criteria used to determine early study endpoints for euthanasia (e.g., percentage of weight loss, tumor size, number of abdominal taps, abdominal distention, anorexia, decreased activity, ruffled fur).

#### **12. Euthanasia or Final Disposition:**

Describe the method of euthanasia by agent, dosage, route, and anatomical site of administration. If animals are not euthanized, state final disposition of the animals.

#### **13. Institutional Animal Care and Use Committee(s) (IACUC) Approval(s):**

Provide written documentation of protocol approval in the form of a letter on institutional stationary signed by the IACUC chair or the IACUC administrator. An IACUC approval letter is required from the facility where the animal research is performed to include any subcontracted facilities. If IACUC approval is pending provide a statement to this effect. Evidence of IACUC review and approval may follow proposal submission, but must be provided prior to the start of animal experimentation.

#### **14. U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service Animal Care Inspection Report:**

Include a copy of the most recent annual USDA Facility Inspection Report for any and all facilities where animal research is performed to include any subcontracted facility.

#### **15. Qualifications:**

List all personnel working with animals under this protocol and all procedures (e.g., surgery, euthanasia, pre and post-operative care), manipulations (e.g., injections, phlebotomy, restraint), and observations each individual will perform. Provide each individual's training, experience, and qualifications to perform these duties. Training should include required institutional courses as described in the Animal Welfare Act regulations (9<sup>th</sup> CFR paragraph 2.32(c)). Qualifications should include educational degrees.

#### **16. Accreditation:**

**One** of the following must be provided for each facility where the animal research will be conducted:

- a. Evidence that the facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC).
- b. A copy of the Institutional Letter of Assurance of Compliance with the "Public Health Service Policy on Humane Care and Use of Laboratory Animals," revised September 1986.
- c. A statement signed by the Institutional Official that the care and use of animals will be performed according to the National Research Council 1996 "Guide for the Care and Use of Laboratory Animals" and applicable Federal regulations.

## 17. Principal Investigator Assurances:

The law specifically requires several written assurances from the P.I. Please read and sign the assurances as indicated (this page may be photocopied and signed)

As the Principal Investigator on this protocol, I acknowledge my responsibilities and provide assurances for the following:

a. Painful Procedures: I assure that discomfort and injury to animals will be limited to that which is unavoidable in the conduct of scientifically valuable research and that analgesic, anesthetic, and/or tranquilizing drugs will be used where indicated and appropriate to minimize pain and/or distress to animals.

b. Animal Use: The animals authorized for use in this protocol will be used only in the activities and in the manner described herein, unless a modification is specifically approved by the IACUC and the U.S. Army Medical Research and Materiel Command prior to its implementation.

c. Duplication of Effort: I have made a reasonable, good faith effort to ensure that this protocol is not an unnecessary duplication of previous experiments.

d. Statistical Assurance: I assure that I have consulted with a qualified individual who evaluated the experimental design with respect to the statistical analysis, and that the minimum number of animals needed for scientific validity will be used.

e. Training: I verify that the personnel performing the animal procedures/manipulations/observations described in this protocol are technically competent and have been properly trained to ensure that no unnecessary pain or distress will be caused to the animals as a result of the procedures/manipulations.

f. Responsibility: I acknowledge the inherent moral, ethical and administrative obligations associated with the performance of this animal use protocol, and I assure that all individuals associated with this project will demonstrate a concern for the health, comfort, welfare, and well-being of the research animals. Additionally, I pledge to conduct this study in the spirit of the fourth "R", which the DOD has embraced, namely, "Responsibility" for implementing animal use alternatives where feasible, and conducting humane and lawful research.

g. Scientific Review: This proposed animal use protocol has received appropriate peer scientific review, and is consistent with good scientific research practice.

---

(Principal Investigator Printed Name)

---

(Principal Investigator Signature and Date)

**NOTE:** For proposals that require the use of nonhuman primates, companion animals, marine mammals, or for research deemed warranted by the USAMRMC, a site visit shall be conducted as necessary by the USAMRMC Animal Care and Use Review Officer or designees.

## **APPENDIX 11 - SAFETY PROGRAM PLAN**

### **Table of Contents**

- 1. Introduction**
- 2. Facility Safety Plan (institution-based)**
  - a. Research Operations/SOPs
  - b. Facility and Equipment Description
  - c. Radioactive Materials
  - d. Hazard Analysis based on Maximum Credible Event
  - e. Biological Defense Research Program Requirements
  - f. Facility Safety Director/Manager Assurance
- 3. Proposal Safety Plan (proposal-based).**
  - a. List of Hazards
  - b. Recombinant DNA Molecules
  - c. Principal Investigator Assurance

### **1. Introduction**

This Appendix contains a description of the requirements, forms, approvals, and assurances relating to safety in the research environment.

NOTE: The Safety Program requirements and approval process have changed for FY01. The Safety Program requirements now consist of two parts: a Facility Safety Plan (institution-based) and a Proposal Safety Plan (proposal-based).

Approval of the Facility Safety Plan is granted on an institution basis rather than on a proposal basis. The Facility Safety Plan shall be institution-based, consist of six parts as outlined on pages 11-2 to 11-3, and be prepared by the Facility Safety Director/Manager of the institution. Each institution is required to submit only one Facility Safety Plan.

Approval of the Proposal Safety Plan is granted on an individual proposal basis. The Proposal Safety Plan shall be related to a specific proposal, consist of two parts as outlined on pages 11-4 to 11-5, and be prepared by the Principal Investigator. Each proposal is required to have an accompanying Proposal Safety Plan.

Facility Safety Plan approvals are granted for a five (5) year period. To determine if your organization has an approved Facility Safety Plan, go to <http://mrmc-www.army.mil/crprcqsohd.asp>.



a. If your organization's name appears on this Institutional Safety Plan Database and approval of the Facility Safety Plan has not expired, then your institution's Facility Safety Plan is not required. Note, however, if you are the Principal Investigator, you are required to provide a Proposal Safety Plan that provides both information specific to the proposal and a signed assurance (See section 3. Proposal Safety Plan, pages 11-4 to 11-5).

b. If either your organization's name does not appear on this Institutional Safety Plan Database or the approval of your institution's Facility Safety Plan has expired, your Facility Safety Manager/Director must provide the U.S. Army Medical Research and Materiel Command's Safety Office with a Facility Safety Plan and a signed assurance, as outlined below (see section 2, Facility Safety Plan, pages 11-2 to 11-3). In addition, if you are the Principal Investigator, you are required to provide a Proposal Safety Plan that provides both information specific to the proposal and a signed assurance (See section 3, Proposal Safety Plan, pages 11-4 to 11-5).

## **2. Facility Safety Plan (institution-based)**

The Facility Safety Director/Manager must provide information from the institutional perspective, as appropriate, for each of the six parts listed below. ). A list of the first five components with a brief description of each is acceptable. Do not send institution safety manuals, although they may be referenced in your submission (web site address is also acceptable). Those parts that do not apply should be listed and labeled as "Not Applicable" or "N/A."

a. Research Operations/Standard Operating Procedures (SOPs). Provide a brief description of the safety procedures relating to the medical research operation of the facility. These should include the following: description of any special skills, training and SOPs that assure safe research operations (Bio-Safety Committee, Radiation Committee, HAZCOM, Blood-borne Pathogens, Chemical Hygiene Plan, etc.), and description of medical surveillance and support.

b. Facility Equipment and Description (related to the research environment). Provide a) a description of the facility; b) a description of personal protective equipment used within the facility; and c) a list of specialized safety equipment such as bio-safety cabinets, hoods, exhausts and ventilation systems.

c. Radioactive Materials. Provide a copy of the Nuclear Regulatory Commission (NRC) or state-approved license.

d. Hazard Analysis (related to the research environment). Provide a description of each hazard identified, the hazard analysis performed based on maximum credible event and the plan to minimize or eliminate each hazard and control risk to laboratory personnel.

e. Biological Defense Research Program Requirements (*Only applicable to the Biological Defense Research Program*). For those institutions where Principal Investigators are supported by U.S. Army Medical Research and Materiel Command (USAMRMC) and are conducting research with Bio-safety Levels 3 and 4 material, a Facility Safety Plan must be prepared in accordance with 32 Code of Federal Regulations 626.18. See URL: [www.access.gpo.gov/nara/cfr/waisidx\\_99/32/cfr626\\_99.html](http://www.access.gpo.gov/nara/cfr/waisidx_99/32/cfr626_99.html) for a copy of the 32 CFR 626.18, Biological Defense Safety Program.

f. Facility Safety Director/Manager Assurance. The Facility Safety Director/Manager must provide the following signed assurance:

## FACILITY SAFETY DIRECTOR/MANAGER ASSURANCE

- ◆ I assure that this institution has an existing institutional safety and occupational health program that meets appropriate Federal, State and local regulations as required by law.
- ◆ I assure that all hazards associated with the research laboratories have been identified, eliminated and/or controlled in such a manner as to provide for a safe research laboratory environment.
- ◆ I accept full responsibility for submitting the Annual Facility Safety Plan Status Report (See section 4) including significant changes in facility, safety equipment, and safety procedures by fax to 301-619-4165, by e-mail to [kenneth.sung@det.amedd.army.mil](mailto:kenneth.sung@det.amedd.army.mil), or by mail to Commanding General, U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RCQ-S, 504 Scott Street, Ft Detrick, MD, 21702-5012.
- ◆ I assure that I have consulted with all current Principal Investigators holding USAMRMC awards concerning this institution's safety policies and procedures and will consult with all future Principal Investigators holding USAMRMC awards concerning institution's safety policies and procedures.

\_\_\_\_\_  
Name of Institution's Safety Director/Manager (print)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

Mailing address: \_\_\_\_\_  
Street

\_\_\_\_\_  
City

\_\_\_\_\_  
State

\_\_\_\_\_  
Zip Code

Phone Number: \_\_\_\_\_

Fax: \_\_\_\_\_

E-mail Address: \_\_\_\_\_

Website: \_\_\_\_\_

### 3. Proposal Safety Plan (proposal-based)

The Principal Investigator must provide one Proposal Safety Plan for each proposal recommended for funding. Provide information specific for the proposal for each of the three (3) parts listed below. Please be concise and brief (1-2 pages).

a. List of Hazards. Identify potential health hazards such as infectious material, toxic substances, radiation, hazardous chemicals, biological hazards and other hazardous materials used in the proposed research.

b. Recombinant DNA (*Only applicable if research involves Recombinant DNA; otherwise, label as N/A*). Research involving recombinant DNA must meet or exceed NIH Guidelines for Research Involving Recombinant DNA Molecules, May 1999 edition. Provide a written approval letter from the organization's Institutional Bio-safety Committee (IBC). If DNA experiments are exempt under the NIH Guidelines, provide a copy of the written exemption notification.

Copies of the above NIH Guidelines are available at:

Fax: (301) 496-9839  
Phone: (301) 496-9838  
Website: <http://www4.nih.gov/od/oba>  
Mail: Office of Recombinant DNA Activities  
National Institutes of Health, MSC 7010  
6000 Executive Boulevard, Suite 302  
Bethesda, MD 20892-7010

c. Principal Investigator Assurance. [The Principal Investigator must provide the following signed assurance:](#)

## PRINCIPAL INVESTIGATOR ASSURANCE

- ◆ I assure that I have involved the Facility Safety Director/Manager in the planning of this research proposal, discussed with him/her all aspects of the proposal that relate to occupational health and safety, and will help him/her prepare the annual Facility Safety Plan Status Report (FSPSR).
- ◆ I assure that I will comply with my institution's safety program and its requirements.
- ◆ I understand that I am directly responsible for all aspects of safety and occupational health specific to my research protocol.
- ◆ I assure that I will report to the Facility Safety Director/Manager any changes in the safety or occupational health practices due to changes in my originally planned research.
- ◆ I assure that hazards associated with my research have been identified, eliminated and/or controlled.
- ◆ I assure that all Safety Plan requirements are in compliance with 32 CFR 626 and 627, "Biological Defense Safety Program and Biological Defense Safety Program, Technical Safety Requirements" (*if applicable*).

\_\_\_\_\_  
Name of Principal Investigator (print)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

Mailing address: \_\_\_\_\_  
Street

\_\_\_\_\_  
City State Zip Code

Phone Number: \_\_\_\_\_

Fax: \_\_\_\_\_

E-mail Address: \_\_\_\_\_

## APPENDIX 12 – REPRESENTATIONS FOR ASSISTANCE AGREEMENTS

**ORGANIZATION:** \_\_\_\_\_ **DATE** \_\_\_\_\_

### 1. TYPE OF BUSINESS ORGANIZATION

The offeror, by checking all applicable boxes, represents that it operates as:

- ☐ an Educational Institution (☐ state-controlled or ☐ private)
- ☐ a Nonprofit Organization
- ☐ a For-Profit Organization
- ☐ an Historically Black College or University
- ☐ a Minority Institution
- ☐ a Small Business
- ☐ a Large Business

### 2. AUTHORIZED NEGOTIATORS

The offeror or quoter represents that the following persons are authorized to negotiate on its behalf with the Government in connection with this request for proposals or quotations:

	Name & Title	Telephone No.	FAX No.
1.	_____	_____	_____
2.	_____	_____	_____
3.	_____	_____	_____

(list names, titles, and telephone and FAX numbers of the authorized negotiators).

### 3. DUNS NUMBER

The offeror is requested to provide the 9-digit DUNS number on the following line:

DUNS Number: \_\_\_\_\_

If the offeror does not have a DUNS number, go to website [www.dnb.com](http://www.dnb.com) or call 1-800-333-0505 for assistance.

### 4. TAXPAYER IDENTIFICATION

#### Definitions.

"Common parent," as used in this solicitation provision, means that corporate entity that owns or controls an affiliated group of corporations that files its Federal income tax returns on a consolidated basis, and of which the offeror is a member.

"Corporate status," as used in this solicitation provision, means a designation as to whether the offeror is a corporate entity, an unincorporated entity (e.g., sole proprietorship or partnership), or a corporation providing medical and health care services.

"Taxpayer Identification Number (TIN)," as used in this solicitation provision, means the number required by the IRS to be used by the offeror in reporting income tax and other returns.

All offerors are required to submit the information required in paragraphs (c) through (e) of this solicitation provision in order to comply with reporting requirements of 26 U.S.C. 6041, 6041A, and 6050M and comply with reporting requirements of 26 U.S.C. 6041, 6041A, and 6050M and implementing regulations issued by the Internal Revenue Service (IRS). If the resulting award is subject to the reporting requirements described in FAR 4.903, the failure or refusal by the offeror to furnish the information may result in a 20 percent reduction of payments otherwise due under the award.

**Taxpayer Identification Number (TIN)**

☐ TIN: \_\_\_\_\_

☐ TIN has been applied for

☐ TIN is not required because:

☐ Offeror is a nonresident alien, foreign corporation, or foreign partnership that does not have income effectively connected with the conduct of a trade or business in the U.S. and does not have an office or place of business or a fiscal paying agent in the U.S.;

☐ Offeror is an agency or instrumentality of a foreign government;

☐ Offeror is an agency or instrumentality of a Federal, state, or local government;

☐ Other. State basis. \_\_\_\_\_

**Corporate Status**

☐ Corporation providing medical and health care services, or engaged in the billing and collecting of payments for such services;

☐ Other corporate entity;

☐ Not a corporate entity;

☐ Sole proprietorship

☐ Partnership

☐ Hospital or extended care facility described in 26 CFR 501(c)(3) that is exempt from taxation under 26 CFR 501(a).

**Common Parent**

☐ Offeror is not owned or controlled by a common parent as defined above.

☐ Name and TIN of common parent:

Name \_\_\_\_\_

TIN \_\_\_\_\_

**5. INSTITUTION CODE**

The Offeror is requested to provide its Federal Interagency Committee on Education (FICE) Institution Code on the following line:

Institution Code: \_\_\_\_\_

## 6. COMMERCIAL AND GOVERNMENT ENTITY (CAGE) CODE REPORTING

The Offeror is requested to enter its CAGE code on the following line and on its offer in the block with its name and address. The CAGE code entered must be for that name and address. Enter CAGE before the number.

CAGE Code: \_\_\_\_\_

If the Offeror does not have a CAGE code, go to website: [www.dlis.dla.mil/cageserv.asp](http://www.dlis.dla.mil/cageserv.asp) and follow the instructions given.

The offeror should not delay submission of the offer pending receipt of a CAGE code.

## 7. RESPONSIBILITY - PERFORMANCE RECORD

Pre-award Survey Information: The Grants Officer must make a determination of a recipient's responsibility prior to awarding a grant or cooperative agreement. The offeror shall complete the following to facilitate this determination.

(a) Yes ☐ No ☐ This organization will be able to accomplish the objectives of the research contained in the schedule. This statement is taking into consideration all existing business commitments, commercial as well as Governmental.

(b) A minimum of two current references (preferably Governmental) for whom contracts, grants or cooperative agreements for same/similar items identified in this proposal have been satisfactorily completed.

\_\_\_\_\_  
NAME OF AGENCY

\_\_\_\_\_  
NAME OF AGENCY

\_\_\_\_\_  
AWARD NO. DATE

\_\_\_\_\_  
AWARD NO. DATE

\_\_\_\_\_  
AMOUNT

\_\_\_\_\_  
AMOUNT

\_\_\_\_\_  
TITLE OF RESEARCH

\_\_\_\_\_  
TITLE OF RESEARCH

\_\_\_\_\_  
GRANTS OFFICER'S NAME

\_\_\_\_\_  
GRANTS OFFICER'S NAME

\_\_\_\_\_  
TELEPHONE NO. AND AREA CODE

\_\_\_\_\_  
TELEPHONE NO. AND AREA CODE

## 8. AWARD/PAYMENT ADDRESS

In the event the offeror is awarded an agreement, the offeror shall indicate below the award address:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

The offeror shall indicate below the address to which any payments should be mailed if that address is different from the award address shown above.

**Payment address:**

---

---

---

---

**9. AUTHORIZATION TO PERFORM**

The Recipient represents that it has been duly authorized to operate and to do business in the country or countries in which this award is to be performed. The Recipient also represents that it will fully comply with all laws, decrees, labor standards, and regulations of such country or countries, during the performance of this award.

**10. FEDERAL DEMONSTRATION PARTNERSHIP (FDP) STATUS**

The recipient represents that it is ☐, is not ☐ an active member eligible to receive an award under the FDP. Information on the FDP is located at [www.fdp3.org](http://www.fdp3.org).

**11. MEDICAL CARE FOR HUMAN SUBJECT RESEARCH**

If the research effort involves the use of human subjects, regardless of the degree of risk, recipient must provide medical care to subjects for research-related injuries at no costs to the subjects, or otherwise arrange for such medical care to be provided at no cost to the subjects. This requirement must be addressed prior to award of an assistance agreement as follows:

The recipient represents that it: ☐ is self insured, ☐ is institutionally insured,

\_\_\_\_\_  
(company)

\_\_\_\_\_  
(policy number)

☐ will apply for an insurance policy for this effort only. Costs to be budgeted separately. The recipient will furnish the Company and Policy number prior to the use of human subject research.

☐ will not perform human subject research.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Type/Printed Name \_\_\_\_\_ Title: \_\_\_\_\_



## APPENDIX 13 – CERTIFICATIONS AND ASSURANCES FOR ASSISTANCE AGREEMENTS

ORGANIZATION: \_\_\_\_\_ DATE: \_\_\_\_\_

*By signing and submitting a proposal or accepting an award, the recipient provides the following assurances and certifications in compliance with the Department of Defense Grants and Agreements, Part 22 and Appendices A and B.*

### 1. Lobbying For Grants And Cooperative Agreements

Submission of this certification is required by Section 1352, Title 31 of the U.S. Code and is a prerequisite for making or entering into a grant or cooperative agreement over \$100,000.

The recipient certifies, to the best of his or her knowledge and belief, that:

(a) No federal appropriated funds have been paid or will be paid, by or on behalf of the undersigned, to any person for influencing or attempting to influence an officer or employee of an agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the making of any Federal grant, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal grant or cooperative agreement.

(b) If any funds other than federal appropriated funds have been paid or will be paid, by or on behalf of the undersigned, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal grant or cooperative agreement, the undersigned shall complete and submit Standard Form LLL, 'Disclosure Form to Report Lobbying,' in accordance with its instructions.

(c) The recipient shall require that the language of this certification be included in the award documents for all subawards at all tiers (including subgrants, contracts under grants and cooperative agreements, and subcontracts) and that all subrecipients shall certify and disclose accordingly.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by Section 1352, Title 31 U.S. Code. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

### 2. Certification Regarding Debarment, Suspension, Proposed Debarment, And Other Responsibility Matters

The Offeror certifies, to the best of its knowledge and belief, that--The Offeror and/or any of its Principals--

(a) Are not presently debarred, suspended, proposed for debarment, or declared ineligible for the award of contracts/assistance agreements by any Federal agency;

(b) Have not within a three-year period preceding this offer, been convicted of or had a civil judgment rendered against them for: commission of fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (Federal, state, or local) contract or subcontract; violation of Federal or state antitrust statutes relating to the submission of offers; or commission of embezzlement, theft, forgery, bribery, falsification or destruction of records, making false statements, or receiving stolen property; and

(c) Are not presently indicted for, or otherwise criminally or civilly charged by a governmental entity with, commission of any of the offenses enumerated in subdivision (a)(1)(i)(B) of this provision.  
(ii) The Offeror has not within a three-year period preceding this offer, had one or more contracts terminated for default by any Federal agency.

"Principals," for the purposes of this certification, means officers; directors; owners; partners; and, persons having primary management or supervisory responsibilities within a business entity (e.g., general manager; plant manager; head of a subsidiary, division, or business segment, and similar positions).

THIS CERTIFICATION CONCERNS A MATTER WITHIN THE JURISDICTION OF AN AGENCY OF THE UNITED STATES AND THE MAKING OF A FALSE, FICTITIOUS, OR FRAUDULENT CERTIFICATION MAY RENDER THE MAKER SUBJECT TO PROSECUTION UNDER SECTION 1001, TITLE 18, UNITED STATES CODE.

The Offeror shall provide immediate written notice to the Grants Officer at any time prior to award, the Offeror learns that its certification was erroneous when submitted or has become erroneous by reason of changed circumstances.

A certification that any of the items in paragraph (a) of this provision exists will not necessarily result in withholding of an award under this solicitation. However, the certification will be considered in connection with a determination of the Offeror's responsibility. Failure of the Offeror to furnish a certification or provide such additional information as requested by the Grants Officer may render the Offeror nonresponsible.

Nothing contained in the foregoing shall be construed to require establishment of a system of records in order to render, in good faith, the certification required by paragraph (a) of this provision. The knowledge and information of an Offeror is not required to exceed that which is normally possessed by a prudent person in the ordinary course of business dealings.

The certification in paragraph (a) of this provision is a material representation of fact upon which reliance was placed when making award. If it is later determined that the Offeror knowingly rendered an erroneous certification, in addition to other remedies available to the Government, the Grants Officer may terminate the award resulting from this solicitation for default.

### **3. Military Recruiting On Campus (domestic educational institutions only)**

As a condition for receipt of funds available to the Department of Defense (DoD) under this award, the recipient assures that it is not an institution that has a policy of denying, and that it is not an institution that effectively prevents, the Secretary of Defense from obtaining for military recruiting purposes:

(a) entry to campuses or access to students on campuses; or

(b) access to directory information pertaining to students. If the recipient is determined, using procedures established by the Secretary of Defense to implement section 558 of Public Law 103-337 (1994), to be such an institution during the period of performance of this agreement, and therefore to be in breach of this clause, the Government will cease all payments of DoD funds under this agreement and all other DoD grants and cooperative agreements, and it may suspend or terminate such grants and agreements unilaterally for material failure to comply with the terms and conditions of award.

### **4. Assurance of Compliance with Title VII of the Civil Rights Act of 1964. (Not Applicable To Foreign Awards)**

Compliance with Title VII of the Civil Rights Act of 1964 (P.L. 88-352) is assured by the signature on the award. In accordance with Title VI of that Act, no person in the United States shall, on the ground of race, color, or national origin, be excluded from participation in, be denied the benefits of, or otherwise subjected to discrimination under any program or activity for which the Applicant receives Federal

financial assistance from the U.S. Government; and hereby gives assurance that it will immediately take any measures necessary to effectuate this agreement.

This assurance is given in consideration of and for the purpose of obtaining any and all Federal grants, cooperative agreements, loans, contracts, property, discounts or other Federal financial assistance extended after the date hereof to the Applicant by the U.S. Government, including installment payments after such date on account of applications for Federal financial assistance which were approved before such date. This assurance is binding on the Applicant, its successors, transferees, and assignees, and the person or persons whose signatures appear on the award.

#### **5. Assurance Of Compliance With Title V Of The Drug-Free Workplace Act Of 1988. (Not Applicable To Foreign Awards)**

Compliance with Title V of the Drug Free Workplace Act of 1988 (P.L. 100-690) is assured by the signature on the award. In accordance with Title V of that Act by requiring that—

(1) A grantee, other than an individual, shall certify to the agency that it will provide a drug-free workplace;

(2) A grantee who is an individual shall certify to the agency that, as a condition of the grant, he or she will not engage in the unlawful manufacture, distribution, dispensing, possession or use of a controlled substance in conducting any activity with the grant.

(3) Requirements implementing the Drug-Free Workplace Act of 1988 for contractors with the agency are found at 48 CFR subparts 9.4, 23.5, and 52.2.

This assurance is given in consideration of and for the purpose of obtaining any and all Federal grants, cooperative agreements, loans, contracts, property, discounts or other Federal financial assistance extended after the date hereof to the Applicant by the U.S. Government, including installment payments after such date on account of applications for Federal financial assistance which were approved before such date. This assurance is binding on the Applicant, its successors, transferees, and assignees, and the person or persons whose signatures appear on the award.

#### **6. Clean Air And Water (Not Applicable To Foreign Awards)**

If the amount of this award exceeds \$100,000, the recipient assures compliance with the Clean Air Act (42 U.S.C. 1857) as amended; the Federal Water Pollution Control Act (33 U.S.C. 1251), as amended; Executive Order No. 11738; and the related regulations of the Environmental Protection Agency (40 CFR, Part 15).

#### **7. Officials Not To Benefit**

The recipient assures that no member of or delegate to Congress, or resident commissioner, shall be admitted to any share or part of this agreement, or to any benefit arising from it, in accordance with 41 U.S.C.22.

#### **8. Preference For U.S. Flag Carriers**

The recipient assures that travel supported by U.S. Government funds under this agreement shall use U.S.-flag air carriers (air carriers holding certificates under 49 U.S.C. 41102) for international air transportation of people and property to the extent that such service is available, in accordance with the International Air Transportation Fair Competitive Practices Act of 1974 (49 U.S.C. 40118) and the interpretative guidelines issued by the Comptroller General of the United States in the March 31, 1981, amendment to the Comptroller General Decision B138942.

## **9. Cargo Preference**

The recipient assures that it will comply with the Cargo Preference act of 1954 (46 U.S.C. 1241) as implemented by Department of Transportation regulations at 46 CFR 381.7, which require that at least 50 percent of equipment, materials or commodities procured or otherwise obtained with U.S. Government funds under this agreement, and which may be transported by ocean vessel, shall be transported on privately owned, U.S.-flag commercial vessels, if available.

## **10. Radioactive Materials**

The recipient assures compliance with the provisions of Title 10 CFR 21. This regulation establishes procedures and requirements for implementation of Section 206 of the Energy Reorganization Act of 1974.

## **11. Recombinant DNA**

The recipient assures that all work involving the use of recombinant DNA will be in compliance with guidance provided at the following website: <http://www4.od.nih.gov/oba/>